GLP-1
Treatment Review
← Peptide library

The evidence reference

Liraglutide

Saxenda

Approved product

Sources checked 2026-10-27

Reading this profile

Start with the path into the study, then consider the audience named in the claim. Read the entry criteria, recruitment description, and reasons people were excluded. If a headline addresses a broad group, ask whether the report explains how its selected participants represent that group. Keep selection at enrollment separate from participation through the end: a report may answer different questions depending on whose results it includes. This reading exercise is about locating the boundary of a conclusion. It does not require deciding that everyone inside or outside a study would have the same experience.

Formulation and route

Subcutaneous injection.

Mechanism

Activates the GLP-1 receptor.

Research evidence

Randomized trials.

Limits of the evidence

Check other products separately.

Safety context

The label warns about severe gastrointestinal reactions.

Questions to take further

  1. How were participants selected for the study described in the report?
  2. Does the headline address a broader population than the enrollment criteria?
  3. Whose results were included when the authors calculated the reported outcome?

Original sources

  1. SAXENDANLM · Checked 2026-10-27

Continue your research

An educational reference from the Comparison Desk. AI-assisted; not reviewed by a licensed clinician. This library does not provide prescriptions or instructions for self-treatment.